Pagibaximab
staphylococcal lipoteichoic acid | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6462H9996N1728O2028S54 |
| Molar mass | 146072.36 g·mol−1 |
  (what is this?) (verify) | |
Pagibaximab is a
staphylococcal sepsis in infants with low birth weight. As of March 2010[update], it is undergoing Phase II/III clinical trials.[1][2]
References
- PMID 19380597.
- ^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |